ANXA1 and type 2 diabetes mellitus: All of the above findings support the conclusions that endogenous ANXA1 prevents the development of insulin-resistance and associated microvascular complications, while pharmacologically administered hrANXA1 attenuates the development of metabolic and secondary microvascular complications in experimental T2D.